menu
    • menu
    [{"orgOrder":0,"company":"University of Bonn","sponsor":"RWTH Aachen University | Ludwig Maximilian University of Munich | University of Jena | Heidelberg University | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bosutinib Monohydrate","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"University of Bonn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Bonn \/ RWTH Aachen University | Ludwig Maximilian University of Munich | University of Jena | Heidelberg University | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Bonn \/ RWTH Aachen University | Ludwig Maximilian University of Munich | University of Jena | Heidelberg University | Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Bosutinib Monohydrate

    Menu

    Bosutinib Monohydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Bonn

                            Country arrow
                            Antibody Engineering
                            Not Confirmed

                            University of Bonn

                            Country arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosutinib Monohydrate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : RWTH Aachen University | Ludwig Maximilian University of Munich | University of Jena | Heidelberg University | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

                            Details : Bosulif is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2017

                            Lead Product(s) : Bosutinib Monohydrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : RWTH Aachen University | Ludwig Maximilian University of Munich | University of Jena | Heidelberg University | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth